Clinical data | |
---|---|
Pronunciation | /ˌvɛnləˈfæksiːn/ |
Trade names | Effexor, Efexor, others[1] |
AHFS/Drugs.com | Monograph |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 42±15%[3] |
Protein binding | 27±2% (parent compound), 30±12% (active metabolite, desvenlafaxine)[4] |
Metabolism | Extensively metabolised by the liver[3][4] |
Elimination half-life | 5±2 h (parent compound for immediate release preparations), 15±6 h (parent compound for extended release preparations), 11±2 h (active metabolite)[3][4] |
Excretion | Kidney (87%; 5% as unchanged drug; 29% as desvenlafaxine and 53% as other metabolites)[3][4] |
Identifiers | |
| |
Chemical and physical data | |
Formula | C17H27NO2 |
Molar mass | 277.408 g·mol−1 |
3D model (JSmol) | |
Chirality | Racemic mixture |
| |
| |
(verify) |
Venlafaxine, sold under the brand name Effexor among others, is an antidepressant medication of the serotonin-norepinephrine reuptake inhibitor (SNRI) class.[6] It is used to treat major depressive disorder (MDD), generalized anxiety disorder (GAD), panic disorder, and social phobia.[6] It may also be used for chronic pain.[7] It is taken by mouth.[6]
Common side effects include loss of appetite, constipation, dry mouth, dizziness, sweating, and sexual problems.[6] Severe side effects include an increased risk of suicide, mania, and serotonin syndrome.[6] Antidepressant withdrawal syndrome may occur if stopped.[6] There are concerns that use during the later part of pregnancy can harm the baby.[6] How it works is not entirely clear but it is believed to involve alterations in neurotransmitters in the brain.[6]
Venlafaxine was approved for medical use in the United States in 1993.[6] It is available as a generic medication.[6] In the United States the wholesale cost per dose is less than US$0.20 as of 2018.[8] In 2017, it was the 49th most commonly prescribed medication in the United States with more than 16 million prescriptions.[9][10]
References
edit- ^ Cite error: The named reference
brands
was invoked but never defined (see the help page). - ^ "Efexor XL 75 mg hard prolonged release capsules - Summary of Product Characteristics (SmPC)". (emc). 16 March 2020. Archived from the original on 7 October 2020. Retrieved 15 April 2020.
- ^ a b c d "Apo-Venlafaxine XR Capsules" (PDF). TGA eBusiness Services. Macquarie Park, NSW: Apotex Pty Ltd. 13 April 2012. Archived from the original on 19 April 2018. Retrieved 6 November 2013.
- ^ a b c d "Venlafaxine (venlafaxine hydrochloride) tablet [Aurobindo Pharma Limited]". DailyMed. Aurobindo Pharma Limited. February 2013. Archived from the original on 30 January 2020. Retrieved 6 November 2013.
- ^ "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 7 November 2020. Retrieved 9 September 2020.
- ^ a b c d e f g h i j "Venlafaxine Hydrochloride Monograph for Professionals". Drugs.com. AHFS. Archived from the original on 27 November 2020. Retrieved 24 December 2018.
- ^ "Antidepressants: Another weapon against chronic pain". Mayo Clinic. Archived from the original on 26 October 2021. Retrieved 25 January 2020.
- ^ "NADAC as of 2018-12-19". Centers for Medicare and Medicaid Services. Archived from the original on 19 December 2018. Retrieved 22 December 2018.
- ^ "The Top 300 of 2020". ClinCalc. Archived from the original on 18 March 2020. Retrieved 11 April 2020.
- ^ "Venlafaxine - Drug Usage Statistics". ClinCalc. Archived from the original on 29 November 2021. Retrieved 11 April 2020.